Pregnancy loss, including recurrent miscarriage and preterm birth, poses significant challenges for expectant mothers and healthcare providers. Progesterone, a crucial hormone for the establishment and maintenance of pregnancy, has been widely investigated as a therapeutic agent to prevent these adverse outcomes. This article reviews the current evidence regarding the efficacy of progesterone therapy in maintaining pregnancy, focusing on its role in preventing recurrent miscarriage and preterm birth. Through a comprehensive synthesis of clinical trials and meta-analyses, this paper aims to provide an updated perspective on its indications, routes of administration, and overall effectiveness. The analysis highlights the nuanced benefits of progesterone in specific high-risk populations and identifies areas for future research to optimize its clinical application.

Progesterone, pregnancy maintenance, recurrent miscarriage, preterm birth, clinical efficacy, hormone therapy.

Csapo, A. I. (1976). Progesterone. American Journal of Obstetrics & Gynecology, 124(4), 391-408.

Mesiano, S., & Jaffe, R. B. (1997). Developmental regulation of placental progesterone synthesis in human pregnancy. Journal of Clinical Endocrinology & Metabolism, 82(2), 2415-2422.

Challis, J. R. G., et al. (2020). Hormonal regulation of parturition. Obstetrics & Gynecology Clinics of North America, 47(3), 335-349.

Royal College of Obstetricians and Gynaecologists. (2011). The investigation and management of recurrent miscarriage. Green-top Guideline No. 17. RCOG.

World Health Organization. (2018). Born too soon: The global action report on preterm birth. World Health Organization.

Schatz, F., et al. (2000). Progesterone: A key hormone for pregnancy maintenance. Journal of the Society for Gynecologic Investigation, 7(1 Suppl), S1-S8.

Wahabi, H. A., et al. (2018). Progestogen for threatened miscarriage. Cochrane Database of Systematic Reviews, (8). Art. No.: CD003598.

Coomarasamy, A., et al. (2023). A randomized trial of progesterone in women with early pregnancy bleeding. The New England Journal of Medicine, 388(25), 2329-2338.

Saccone, G., et al. (2017). Progestogen for recurrent miscarriage: a systematic review and meta-analysis. Journal of Maternal-Fetal & Neonatal Medicine, 30(20), 2496-2503.

Romero, R., et al. (2017). Vaginal progesterone in women with an asymptomatic short cervix and a history of spontaneous preterm birth: a systematic review and meta-analysis of randomized controlled trials. American Journal of Obstetrics & Gynecology, 216(1), 10-29.e10.

Saccone, G., et al. (2017). Vaginal progesterone for the prevention of preterm birth in women with a short cervical length: a systematic review and meta-analysis of randomized controlled trials. American Journal of Obstetrics & Gynecology, 217(3), 291-306.

Fonseca, E. B., et al. (2007). Prophylactic administration of progesterone by intramuscular injection in women with a history of recurrent preterm birth. American Journal of Obstetrics & Gynecology, 197(5), 452.e1-452.e8.

Meis, P. J., et al. (2023). 17-hydroxyprogesterone caproate for the prevention of recurrent preterm birth. The New England Journal of Medicine, 388(18), 1776-1786.

Conde-Agudelo, A., et al. (2020). Maternal and perinatal outcomes with progesterone for preventing preterm birth: a systematic review and meta-analysis of randomized controlled trials. American Journal of Obstetrics & Gynecology, 223(1), 39-56.e10.

Norwitz, E. R., & Schlabritz-Loutsevitch, N. E. (2016). Progesterone: The guardian of pregnancy. Seminars in Reproductive Medicine, 34(3), 108-118.

Society for Maternal-Fetal Medicine (SMFM) Publications Committee. (2017). Clinical Guideline: Progesterone and Preterm Birth Prevention. American Journal of Obstetrics & Gynecology, 217(6), B1-B13.

American College of Obstetricians and Gynecologists (ACOG). (2017). Practice Bulletin No. 130: Prediction and Prevention of Preterm Birth. Obstetrics & Gynecology, 120(4), 964-973.